Skip to main content

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Completed · Phase 3 · NCT05882045

Conditions: Obesity, Cardiovascular Diseases

At a glance

Research payments reported, 2025
$3.9M
U.S. investigators named
56
Sites paid
55
Planned or actual enrollment
1,946

About the trial

Sponsor
Eli Lilly and Company
Tested
Retatrutide (drug), Placebo (drug)
Dates
Started 2023-05-30; completion 2026-05-14
Results posted
Not yet

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

From ClinicalTrials.gov, last updated 2026-07-30. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $3.9M in research payments for this study in 2025 (113 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Latin Clinical Trial Center Inc $300,786
  • Valley Clinical Trials Inc $294,349
  • Pacific Diabetes and Endocrine Center $265,980
  • Indago Research & Health Center Inc $229,056
  • Clinical Neuroscience Solutions DBA Cns Hlthcare $213,491
  • Northwestern University $179,217
  • Southern Endocrinology Associates PA $158,851
  • Cotton Oneil Msd of Stormont Vail Healthcare $158,146
  • Studymetrix Research LLC $153,752
  • Medvadis Research Corp LLC $125,288
  • Sleep Therapy & Research Center LLC $122,180
  • University of Pittsburgh Physicians $112,161
  • Charter Research LLC $109,557
  • Ima Evaluations LLC DBA Ima Clinical Research $103,989
  • Consano Clinical Research LLC $101,071
  • Progressive Medical Concepts LLC $94,811
  • Weill Medical College $80,131
  • Chase Medical Research LLC $77,182
  • Wrightsville Family Practice $75,880
  • Compass Point Research Inc $75,595
  • Altoona Center for Clinical Research PC $73,602
  • Tribe Clinical Research LLC $71,291
  • Las Vegas Medical Research LLC $69,972
  • Velocity Clinical Research Inc $68,123
  • Carteret Medical Group LLC $66,412
  • Neuro PAin Medical Center Inc $57,023
  • Palm Research Center Inc $52,651
  • Pinnacle Clinical Research LLC $51,510
  • Iowa Diabetes and Endocrinology Rsrch Cntr $45,492
  • Texas Diabetes and Endocrinology PA $41,476
  • Rochester Clinical Research Inc $39,176
  • Rainier Clinical Research Center $34,228
  • Collaborative Neuroscience Research LLC $26,037
  • Advanced Research Inc $24,415
  • Ponce School of Medicine $24,116
  • St Luke's Regional Medical Center, ID $21,833
  • South Texas Clinical Research $16,133
  • Clinical Research Management Group $13,360
  • Great Lakes Clinical Trials $10,954
  • Cleveland Clinic, OH $10,274
  • Prairie Education and Research Coop $3,446
  • Sky Clinical Research Network Group $826
  • Mehrdad Kevin Ariani MD $810
  • Andrew J Lewin Med DBA National Rsrch Institute $675
  • Advanced Research Institute $588
  • Clinical Research Advantage $570
  • Pinnacle Clinical Research PLLC $570
  • Amici Clinical Research LLC $465
  • Collaborative Neuroscience Network Inc $465
  • Hattiesburg Clinic PA $405
  • Rainier Clinical Research Center Inc $270
  • St Luke's $225
  • University of Pittsburgh $161
  • $64
  • Medex Healthcare Research Inc $10
  • Stormont-Vail Healthcare Inc $6

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.